In vitro evaluation of effectiveness of synergistic cannabinoid- and chemotherapeutic-loaded nanocarriers in glioblastoma treatment

For centuries, derivatives of Cannabis sativa have been employed for medicinal, recreational, and industrial purposes. Historically, ancient China provided the first documented evidence of its medical use, with subsequent utilization noted in Europe and Asia​1​. By the 19th century, European physicians applied cannabis extracts to treat conditions like tetanus, convulsions, and mental disorders. Despite its medical potential, regulatory challenges, such as the Marijuana Tax Act of 1937, curtailed its use in modern pharmacology​2​. 

Cannabinoids—bioactive compounds from Cannabis sativa—have demonstrated a range of biological effects, including anti-cancer properties. These effects involve both canonical cannabinoid receptor (CBR)-dependent pathways and alternative mechanisms mediated through transient receptor potential (TRP) channels. Notable studies highlight cannabinoid interactions with TRPV1, TRPV2, TRPM8, and TRPA1, which modulate cancer cell metabolism, induce apoptosis, and inhibit tumour progression. Recent findings also suggest that cannabinoids can influence extracellular vesicle (EV) secretion, altering tumor-promoting and suppressive microRNA profiles.​3–6​ 

Glioblastoma (GBM), a highly aggressive brain cancer, presents unique therapeutic challenges due to the protective nature of the blood-brain barrier (BBB). The BBB restricts the passage of most chemotherapeutic agents, significantly limiting their effectiveness​7​. Nanoparticle-based drug delivery systems offer a promising solution to this challenge. These nanoscale carriers can cross the BBB via receptor-mediated endocytosis, transcytosis, or temporary BBB disruption, enabling the targeted delivery of therapeutic agents to brain tumours​7​. In particular, polysaccharide-based nanocarriers are gaining attention due to their biocompatibility, stability, and ability to encapsulate both hydrophilic and hydrophobic drugs. 

This project proposes to leverage novel polysaccharide-based nanocarriers loaded with cannabinoids and chemotherapeutic agents to evaluate their synergistic effects on glioblastoma. By combining the BBB-crossing capability of nanoparticles with the therapeutic potential of cannabinoids, this study aims to advance the treatment of glioblastoma. 

To apply for this project, please submit an application for October 2025 entry at this link (How to apply for a research degree (PhD, Professional Doctorate, MPhil, MA/MSc by Research) – Kingston University London) and ensure that you upload a document as part of your application that states you are applying for a studentship and the name of the project that you are applying for.